SLC5A2 and type 2 diabetes mellitus: SGLT-2 inhibitors were found to be more effective than sulfonylureas or DPP4-inhibitors in reducing the hazards of hospital admission for heart failure (v DPP-4 inhibitors) and kidney disease progression (v sulfonylureas) for a broad population of people with T2DM